Addition of the FLT3/multikinase inhibitor midostaurin to initial chemotherapy for FLT3-mutated AML has prolonged patient survival [22], and gilteritinib [23] and other FLT3 inhibitors have activity in relapsed and refractory disease, but outcomes remain suboptimal [5]. Here, FLT3 is linked to acute myeloid leukemia.